<unk>  is an tyrosine kinase inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.   Common adverse reactions include diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot syndrome, weight decreased, vomiting, asthenia, and constipation.
Axitinib
Ceritinib
Sunitinib
Afatinib
Erdafitinib
Dacomitinib
Neratinib
Baricitinib